Rani Therapeutics Holdings (RANI) Long-Term Debt Issuances (2020 - 2022)
Rani Therapeutics Holdings (RANI) posted Long-Term Debt Issuances of $14.9 million for Q4 2022, up 1.58% on a QoQ basis from $14.7 million in Q3 2022.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Long-Term Debt Issuances (2020 - 2022) Analysis & Trends
Rani Therapeutics Holdings has reported Long-Term Debt Issuances for 3 years, with the latest figure at $14.9 million in Q4 2022.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $14.9 million in Q4 2022; TTM through Dec 2023 was $29.6 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $29.6 million, up 1619.42% from the prior year.
- Long-Term Debt Issuances was $14.9 million for Q4 2022 at Rani Therapeutics Holdings, up from $14.7 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $14.9 million in Q4 2022, with the low at $1.5 million in Q3 2020.
- Average Long-Term Debt Issuances over 3 years is $8.2 million, with a median of $8.2 million recorded in 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 14.90 Mn |
| Sep 30, 2022 | 14.67 Mn |
| Mar 31, 2021 | 1.72 Mn |
| Sep 30, 2020 | 1.53 Mn |